Please login to the form below

Not currently logged in
Email:
Password:

Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

Ocrevus helps Roche shrug off biosimilars in 2018

Ocrevus helps Roche shrug off biosimilars in 2018

Multiple sclerosis therapy Ocrevus (ocrelizumab, pictured above) was once again the star of the show, rising 172% to 2.35bn francs in its first full calendar year on the market, making

Latest news

  • Novartis: pipeline will generate 60 filings in three years Novartis: pipeline will generate 60 filings in three years

    Following after in MS is ofatumumab, a potential rival to Roche’s fast-growing CD20-targeting drug Ocrevus (ocrelizumab) that is already approved to treat blood cancers under the Arzerra (brand

  • Roche’s new flu pill Xofluza approved in US Roche’s new flu pill Xofluza approved in US

    This week saw the company unveil strong Q3 results, which managed to overcome the biosimilar onslaught, thanks to growth in new products such as multiple sclerosis drug Ocrevus.

  • Spinraza lifts Biogen ahead of Alzheimer’s data Spinraza lifts Biogen ahead of Alzheimer’s data

    from newer drugs such as Roche’s Ocrevus (ocrelizumab). ... MS drug sales came in at $2.3bn, with Tecfidera static at $1.09bn, and while Biogen gets a royalty stream from Ocrevus sales, that did little to counteract the impact

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    Sales of Roche’s new multiple sclerosis therapy Ocrevus more than tripled in the first nine months of 2018, helping to compensate for the loss of patent protection on its older ... Ocrevus (ocrelizumab) only made its debut in the US last year, but has

  • Novartis files for approval of MS drug in EU, US Novartis files for approval of MS drug in EU, US

    That includes Roche‘s new therapy Ocrevus (ocrelizumab), a humanised monoclonal antibody designed to selectively target CD20-positive B cells, which has been approved in relapsing forms of MS and primary ... Ocrevus’ indications does however cover

More from news
Approximately 16 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics